Search for content, post, videos

Orion’s partner receives FDA approval

Orion research
Orion’s collaboration partner Bayer has announced the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for the oral androgen receptor inhibitor (ARi) darolutamide in combination with docetaxel for the treatment of patients with metastatic hormone-sens
Already a subscriber Login

You have read all your free articles, to continue reading subscribe to read the rest of this content.